Long-Term Real-World Outcomes of First-Line Pembrolizumab Monotherapy for Metastatic Non-Small Cell Lung Cancer With ≥50% Expression of Programmed Cell Death-Ligand 1

OBJECTIVES: Immune checkpoint inhibitors (ICIs) of programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) have been rapidly adopted in US clinical practice for first-line therapy of metastatic non-small cell lung cancer (NSCLC) since regulatory approval in October 2016, and a better und...

Descripción completa

Detalles Bibliográficos
Autores principales: Velcheti, Vamsidhar, Hu, Xiaohan, Yang, Lingfeng, Pietanza, M. Catherine, Burke, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990758/
https://www.ncbi.nlm.nih.gov/pubmed/35402266
http://dx.doi.org/10.3389/fonc.2022.834761

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990758/
https://www.ncbi.nlm.nih.gov/pubmed/35402266
http://dx.doi.org/10.3389/fonc.2022.834761

Ejemplares similares